Syros to Participate in Upcoming Investor Conferences
16 November 2021 - 11:30PM
Business Wire
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development
of medicines that control the expression of genes, today announced
that its Chief Executive Officer, Nancy Simonian, M.D., will
participate in fireside chats at two upcoming virtual investor
conferences. Management will also be available for one-on-one
meetings.
Piper Sandler 33rd Annual Healthcare Conference Date:
Tuesday, November 23, 2021 Presentation Time: A pre-recorded
fireside chat will be made available on-demand beginning at 10:00
a.m. ET
JMP Securities Hematology and Oncology Summit Date:
Monday, December 6, 2021 Presentation Time: 10:40 a.m. ET
To access the webcasts and subsequent archived recording of each
fireside chat, please visit the Investors & Media section of
the Syros website at www.syros.com. An archived replay of each
webcast will be available for approximately 30 days following each
presentation.
About Syros Pharmaceuticals Syros is redefining the power
of small molecules to control the expression of genes. Based on its
unique ability to elucidate regulatory regions of the genome, Syros
aims to develop medicines that provide a profound benefit for
patients with diseases that have eluded other genomics-based
approaches. Syros is advancing a robust clinical-stage pipeline,
including: tamibarotene, a first-in-class oral selective RARα
agonist in RARA-positive patients with higher-risk myelodysplastic
syndrome and acute myeloid leukemia; SY-2101, a novel oral form of
arsenic trioxide in patients with acute promyelocytic leukemia; and
SY-5609, a highly selective and potent oral CDK7 inhibitor in
patients with select solid tumors and blood cancers. Syros also has
multiple preclinical and discovery programs in oncology and
monogenic diseases. For more information, visit www.syros.com and
follow us on Twitter (@SyrosPharma) and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211116005077/en/
Media Contact: Courtney Solberg Syros Pharmaceuticals
917-698-9253 csolberg@syros.com
Investor Contact: Hannah Deresiewicz Stern Investor
Relations, Inc. 212-362-1200 hannah.deresiewicz@sternir.com
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Apr 2024 to May 2024
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From May 2023 to May 2024